Bucindolol, a beta-blocker that never made it to the market because a patient study showed it did not reduce the risk of death due to high blood pressure and heart failure, may be making a comeback. According to the Wall Street Journal, researchers report that heart failure patients with a specific genetic mutation given the drug were 48 percent less likely to die of heart-related problems and 44 percent less likely to be hospitalized, as compared to those given placebo. According to a press release, about half of US heart failure patients have this mutation. The release also says that FDA has accepted a New Drug Application for bucindolol.
Try, Try, Try Again: Sep 23, 2008
Sep 23, 2008